Oncotelic Therapeutics and Sapu Bioscience Announce Publication on Sub-15 nm Nanoparticles in International Journal of Molecular Sciences
November 12, 2025 | Agoura Hills, CA & San Diego, CA — Oncotelic Therapeutics, Inc. (OTLC) and JV partner Sapu Bioscience announced the publication of their review article, “Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential,” in the International Journal of Molecular Sciences (DOI: 10.3390/ijms262210842).
Defining a New Size Regime in Nanomedicine
Ultrasmall nanoparticles below 15 nm exhibit unique biological behaviors not seen in conventional 50–200 nm nanodrugs, including deeper tumor penetration and reduced RES uptake.
- Improved access to dense or poorly vascularized tissues
- Reduced reticuloendothelial sequestration and organ burden
- Enhanced ability to cross biological barriers
- Quantum-scale surface behavior enabling multifunctional applications
Impact on the Sapu Nano Pipeline
The review supports Sapu Nano’s sub-20 nm Deciparticle™ platform, providing scientific rationale for programs such as SAPU-003, an intravenous Deciparticle™ formulation of everolimus.
About the Publication
Sub-15 nm Nanoparticles for Drug Delivery
Authors: Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, Cynthia Lee Published: November 8, 2025